Evotec AG (NASDAQ:EVTCY)

BRIEF

published on 04/24/2025 at 07:35, 9 months 6 days ago

Evotec and Bristol Myers Squibb's Protein Degradation Partnership Yields Progress

Evotec SE Oncology Research Bristol Myers Squibb Molecular Glue Degraders $75 Million Payment
PRESS RELEASE

published on 04/24/2025 at 07:30, 9 months 6 days ago

Evotec announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb
Evotec SE announces significant progress in strategic protein degradation collaboration with Bristol Myers Squibb, expanding pipeline of molecular glue degraders for unmet medical needs. Performance-based payments totaling US$75 m

Evotec SE Collaboration Bristol Myers Squibb Molecular Glue Degraders Protein Degradation
BRIEF

published on 04/17/2025 at 07:05, 9 months 13 days ago

Evotec SE Outlines New Strategy with 2025 Guidance Following Strong Q4 2024 Performance

Evotec SE 2025 Strategy Partnerships Growth Guidance Q4 2024 Results
PRESS RELEASE

published on 04/17/2025 at 07:00, 9 months 13 days ago

Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results
Evotec SE unveils new strategy and provides 2025 guidance with strong Q4 2024 results, focusing on drug discovery and sustainable growth

Evotec SE Sustainable Growth New Strategy 2025 Guidance Q4 2024 Results
BRIEF

published on 04/10/2025 at 11:30, 9 months 20 days ago

Evotec SE to Release 2024 Financial Results on April 17, 2025

Financial Results Conference Call Evotec SE Webcast Therapeutics
PRESS RELEASE

published on 04/10/2025 at 11:25, 9 months 20 days ago

Evotec SE to announce results for financial year 2024 on 17 April 2025
Evotec SE to announce financial results for 2024 on April 17, 2025, followed by a conference call discussing strategic review and updates. Webcast and dial-in details provided

Financial Results Conference Call Evotec SE Webcast Strategic Review
BRIEF

published on 03/04/2025 at 07:35, 10 months 26 days ago

Evotec's Neuroscience Collaboration with Bristol Myers Squibb Progresses

Strategic Partnership Evotec SE Innovative Treatments Bristol Myers Squibb Neurodegeneration
PRESS RELEASE

published on 03/04/2025 at 07:30, 10 months 26 days ago

Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Evotec SE announces key progress in neuroscience collaboration with Bristol Myers Squibb, receiving a $20 million payment for neurodegeneration research

Evotec SE Bristol Myers Squibb Neuroscience Collaboration Neurodegeneration Research Progress
BRIEF

published on 02/26/2025 at 07:35, 11 months 4 days ago

Evotec Announces Executive Transition in CFO Role

Sustainable Growth Management Change Evotec Financial Leadership Paul Hitchin
PRESS RELEASE

published on 02/26/2025 at 07:30, 11 months 4 days ago

Evotec announces change in Management Board
Evotec SE announces change in Management Board with Laetitia Rouxel stepping down as CFO and Paul Hitchin appointed as her successor. Rouxel to leave the Company on 31st March 2025. Hitchin brings over 20 years of finance leadership experience

CFO Evotec SE Management Board Paul Hitchin Laetitia Rouxel

Published on 01/30/2026 at 14:00, 5 hours 34 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 10 hours 59 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 11 hours 34 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 17 hours 19 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 19 hours 34 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 19:13, 21 minutes ago

Total Voting Rights
Published on 01/30/2026 at 18:31, 1 hour 3 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/30/2026 at 18:30, 1 hour 4 minutes ago

HOL-Holdings in Company
Published on 01/30/2026 at 18:23, 1 hour 11 minutes ago

TVR-Total Voting Rights
Published on 01/30/2026 at 18:17, 1 hour 17 minutes ago

POS-Transaction in Own Shares

View all EQS

Published on 01/30/2026 at 17:45, 1 hour 49 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 11 hours 34 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 1 hour ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 1 hour ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News